Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01523717 · ClinicalTrials.gov registry record
Procalcitonin Monitoring Sepsis Study
A clinical trial, sponsored by Brahms.
- Completed
- Registry status
- 858
- Enrollment target
NCT01523717: Completed study, sponsored by Brahms.
NCT01523717 is a clinical trial that has completed, run by Brahms. The registered enrollment target is 858 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01523717 has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 858 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
Primary Outcome
participants will be followed up for 28 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 858 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-03 |
What the finished NCT01523717 record still lists
NCT01523717 is an observational study that tracks outcomes without assigning an intervention. The registered 858 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01523717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01523717 about?
NCT01523717 is a clinical study titled "Procalcitonin Monitoring Sepsis Study". The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
What is the current status of trial NCT01523717?
This trial is currently completed. The enrollment target is 858 participants. The study started on 2011-12. Estimated completion is 2014-03.
Who is sponsoring clinical trial NCT01523717?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia